Effects of sorbent suspension dialysis on plasma amino acid levels in cirrhotic patients with refractory hepatic encephalopathy

International Journal of Artificial Organs

Volumn 25, Issue 10, 2002, Pages 923-928

  Bauer, Edith ^a   Gendo, A ^a   Madl, C ^a   Garo, F ^b   Roth, E ^b   Kramer, L ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Amino acids; Artificial liver support; BioLogic DT System; Encephalopathy

Indexed keywords

ARTIFICIAL ORGANS; DETOXIFICATION; DIALYSIS; SORBENTS; SORPTION;

AMINO-ACIDS; AROMATIC AMINO ACID; ARTIFICIAL LIVER; ARTIFICIAL LIVER SUPPORT; BIOLOGIC-DT SYSTEM; DIALYSIS SYSTEMS; HEPATIC ENCEPHALOPATHIES; MEDICAL TREATMENT; PLASMA AMINO ACIDS; PROSPECTIVE STUDY;

AMINO ACIDS;

ALANINE; AMINO ACID; ARGININE; AROMATIC AMINO ACID; ASPARAGINE; ASPARTIC ACID; BRANCHED CHAIN AMINO ACID; CITRULLINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; ISOLEUCINE; LACTULOSE; LEUCINE; METHIONINE; PAROMOMYCIN; PHENYLALANINE; SERINE; SORBENT; TAURINE; THREONINE; TRYPTOPHAN; TYROSINE; VALINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIALYSIS; DISEASE CLASSIFICATION; FEMALE; FLUID THERAPY; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; MALE; PARENTERAL NUTRITION; PATHOGENESIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUSPENSION; TREATMENT PLANNING;

EID: 0036816527     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880202501005     Document Type: Article

References (23)

1. Ferenci P, Müller C. Hepatic encephalopathy: Treatment. In: Burroughs A, Feagan B, Mc Donald JWB, eds. Evidence Based Gastroenterology. London: BMJ Books, 1999: pp. 443-55.
2. Butterworth RF, Giuère JF, Michaud J, Lavoie J, Pomeir-Layargues G. Ammonia: A key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12.
3. Mullen KD, Jones EA. Natural benzodiazepines and hepatic encephalopathy. Semin Liver Dis 1996; 16: 255-64.
4. Blei AT. Brain edema and portal-systemic encephalopathy. Liver Transpl 2000; 6 (suppl): S14-20.
5. Kramer L, Gendo A, Madi C. A controlled study of sorbent suspension dialysis in chronic liver disease and hepatic encephalopathy. Int J Artif Organs 2001; 24: 434-42.
6. Ash SR, Blake DE, Carr DJ, et al. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15: 151-61.
7. Fischer JE, Rosen HM, Ebei AM, et al. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 1976; 80: 77-91.
8. Rosen HM, Yoshimura N, Hodgman JM, et al. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 1977; 72: 483-7.
9. Iob V, Coon WW, Sloan H. Altered clearance of free amino acids from plasma of patients with cirrhosis of the liver. J Surg Res 1966; 6: 233-9.
10. Iob V, Coon WW, Sloan M. Free amino acids in liver, plasma and muscle of patients with cirrhosis in liver. J Surg Res 1967; 7: 41-3.
11. Warren J, Denis J, Desurmont P, et al. Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 1983; 3: 457-80.
12. Michel H, Bones P, Aubin JP. Treatment of acute hepatic encephalopathy in cirrhotics with a branched-chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 1985; 5: 282-9.
13. Steczko J, Bax KC, Ash SR. Effect of hemodiabsorption and sorbent-based pheresis on amino acid levels in hepatic failure. Int J Artif Organs 2000; 23: 375-88.
14. Conn HO, Lieberthal MM. The Hepatic Coma Syndromes and Lactulose. Baltimore: Williams & Wilkins, 1979.
15. Kramer L, Gendo A, Madi C, et al. Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. Am J Kidney Dis 2000; 36: 1193-200.
16. Druml W, Heinzel G, Kleinberger G. Amino acid kinetics in patients with sepsis. Am J Clin Nutr 2001; 73: 908-13.
17. Druml W, Fischer M, Liebisch B, Lenz K, Roth E. Elimination of amino acids in renal failure. Am J Clin Nutr 2000; 72: 1237-9.
18. Mullen KD, Szauter KM, Kaminsky-Russ K. "Endogenous" benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1986; 336: 81-3.
19. Cordoba J, Blei AT, Mujais S. Determinants of ammonia clearance by hemodialysis. Artif Organs 1996; 20: 800-3.
20. Cascino A, Cangiano C, Fiaccadori F, et al. Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. Dig Dis Sci 1982; 27: 828-32.
21. Rössle M, Luft M, Herz R, Klein B, Lehmann M, Gerok W. Amino acid, ammonia and neurotransmitter concentrations in hepatic encephalopathy: Serial analysis in plasma and cerebrospinal fluid during treatment with an adapted amino acid solution. Klin Wochenschrift 1984; 62: 867-75.
22. Plauth M, Egberts EH, Hamster W, et al. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study. J Hepatol 1993; 17: 308-14.
23. Albrecht J, Jones EA. Hepatic encephalopathy: Molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999; 170: 138-46.